Hims Daily (May 29, 2025)

Credit card data is curling higher 👀

Stock Price: $52.36

• Today: -$0.98 (-1.84%)

• YTD: +$28.18 (+116.54%)

• Q2: +$22.81 (+77.19%)

🚨 JUST IN — credit card data for the week ending May 18 was the second strongest of Q2. Our full analysis + new revenue prediction drops tomorrow. Upgrade to paid for access!

What’s Happening

• Pullback on light volume. HIMS fell nearly 2% to $52.36 today despite an early surge to $55.58.

  • Volume came in at just 14M today. WAY below average and the sleepiest session in many weeks. That said, the key $51–52 support zone held firm for the fourth time since early May

• Tariff headlines whipsawed the tape. A rollercoaster of U.S. court rulings on Trump’s tariffs rattled markets. Last night, the U.S. Court of International Trade blocked the tariffs. This afternoon, the Appeals Court reinstated them.

• Technical setup remains bullish. Shares are coiled and consolidating right on the 20-day EMA. Chartists point to a break above $55 as the likely trigger for a $60+ move, with downside support near $48 if these levels fail.

• 🚨 CVS announced today that it is closing 271 more stores. That’s nearly 1.2k closures since 2022. As the Hims-obsessed Twitter account, Nighthawk Capital, put it: “The future of healthcare isn’t in retail aisles. It’s in your pocket.” Couldn’t agree more, Nighthawk. 🫡

• Martin Shkreli said on Amit’s livestream today that Hims’ “valuation is still very reasonable”. Meanwhile, we dropped our podcast with Antonio Linares today. Feedback has been fantastic so far. Antonio doubled down on the idea that Hims is a 100x — from here 🤯 (WATCH THE INTERVIEW)

Catalysts

• Hims recently raised $1B - acquisition soon?

• Move from the Russell 2000 to the Russell 1000 could drive institutional buying. Index reconstitution set for late June.

• Pharma tariffs?

• Partnership with Eli Lilly?

• Any incremental details on the Novo Nordisk roadmap

• Upcoming OFA vs. FDA case on semaglutide

Top Tweets